Endocyte (ECYT) to Focus on Promising CAR-T Cell Platform – Nasdaq
Nasdaq |
Endocyte (ECYT) to Focus on Promising CAR–T Cell Platform
Nasdaq In Jun 2017, Endocyte announced plans to reduce its workforce by about 40% in order to divert more of its resources toward valuable opportunities The company also looks forward to shift its focus on its most promising programs, which include its CAR T … |
